RVTY
Health check
See the tests
- ✓Positive net income
- ✓Positive operating cash flow
- ✗Return on assets improved
- ✓Cash flow above net income
- ✓Long-term debt / assets fell
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Computed by Coteau from the company's SEC filings (latest balance sheet Jul 5, 2026). Descriptive, not a forecast.
Live chart
What they do
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility.
For information only · Important disclosures
Grades vs sector
Momentum83rd percentile in sectorA-
Percentile within its GICS sector across the S&P 1500.
Growth15th percentile in sectorD-
Percentile within its GICS sector across the S&P 1500.
Value24th percentile in sectorD+
Percentile within its GICS sector across the S&P 1500.
Profitability41st percentile in sectorC
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-07-05). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.06 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
pricier
pricier
pricier
pricier
cheaper
pricier
Forward EPS $5.89 vs trailing $2.10 (+181% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 6/9 · last two fiscal years
Altman Z-score 3.3 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $2.9B | $241.2M | $509.4M |
| 2024 | $2.8B | $270.4M | $541.7M |
| 2023 | $2.8B | $693.1M | $9.9M |
| 2023 | $3.3B | $569.2M | $594.2M |
| 2022 | $3.8B | $943.2M | $1.3B |
| 2021 | $2.7B | $727.9M | $828.5M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -4.8%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | 1.22 | 1.41 | +15.9% |
| 2026-05-05 | 1.01 | 1.06 | +4.5% |
| 2026-02-02 | 1.58 | 1.70 | +7.8% |
| 2025-10-27 | 1.14 | 1.18 | +3.6% |
| 2025-07-28 | 1.14 | 1.18 | +3.4% |
| 2025-04-28 | 0.95 | 1.01 | +6.4% |
| 2025-01-31 | 1.38 | 1.42 | +3.1% |
| 2024-11-04 | 1.13 | 1.28 | +13.6% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $729.7M | +1.3% |
| 2026-03-31 | $711.1M | – |
| 2025-12-31 | $772.1M | – |
| 2025-09-30 | $698.9M | – |
| 2025-06-30 | $720.3M | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Recent dividends
Stats refreshed 2026-10-22 21:45:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Free to use. No card, no ads, no auto-renew.
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026